No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
92 |
4. Check minimum number of eventsNone |
92 |
5. Include endpointsNone |
92 |
6. Filter based on genotype QC (FinnGen only) |
92 |
Control definitions (FinnGen only)
- Control exclude
- L12_DISORDSKINAPPENDIX
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L60
- Name in latin
- Onychogryposis
Similar endpoints
↥List of similar endpoints to
Onychogryphosis
based on the number of shared cases.
Similar with more cases:
- Nail disorders
- Disorders of skin appendages
- Diseases of the skin and subcutaneous tissue
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1009 | 654 | 347 |
| Only index persons | 760 | 483 | 277 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 55.13 | 56.57 | 52.13 |
| Only index persons | 52.59 | 53.62 | 50.79 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 92 | 59 | 33 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | 49.23 | 48.61 | 50.34 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 84
- Matched controls
- 840
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L60.2
ICD-10 Finland
Onychogryphosis
+∞
82.3
65
*
70305
ICD-8 Finland
Diseases of nail, Onychogryphosis
+∞
15.0
14
*
QDH00
NOMESCO Finland
Avulsion of toe nail
+∞
15.0
14
*
L84
ICD-10 Finland
Corns and callosities
16.1
10.2
16
12
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
13.7
7.9
13
11
L60.0
ICD-10 Finland
Ingrowing nail
11.6
7.3
13
13
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
10.7
7.1
13
14
V03AE01
ATC
polystyrene sulfonate; oral
43.7
6.9
8
*
E10.4
ICD-10 Finland
Type 1 diabetes mellitus, With neurological complications
43.7
6.9
8
*
B35.1
ICD-10 Finland
Tinea unguium
7.3
6.9
16
26
L03.0
ICD-10 Finland
Cellulitis of finger and toe
6.8
6.5
16
28
PD4BC
NOMESCO Finland
Extensive arterigography of lower extremity with X-ray
75.3
6.5
7
*
E000001
ATC
NA
3.9
6.2
27
90
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
4.9
6.1
20
50
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
4.5
6.1
22
61
SPAT1229
SPAT
Assessment of need for aid
6.1
6.1
16
31
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
53
291
2.94
6.02
2.0
1.8
89.6
97.8
pmol/l
0.64
28
144
60
354
3.00
5.94
4.4
3.8
—
—
—
0
0
37
176
2.84
5.37
2.8
2.2
—
—
—
0
0
12
30
4.45
4.60
2.1
2.0
—
—
—
0
0
12
31
4.30
4.41
2.2
2.4
—
—
—
0
0
17
59
3.31
4.16
4.5
3.2
5.7
5.8
kpa
0.07
17
59
33
167
2.52
4.07
2.5
2.0
3.4
3.3
mg/l
0.08
33
142
21
85
2.91
3.98
16.5
4.2
1.1
1.0
mmol/l
0.58
21
75
24
106
2.71
3.87
2.2
2.0
—
—
—
0
0
24
107
2.68
3.80
6.6
4.5
35.5
32.2
%
0.50
19
71
33
177
2.35
3.52
1.5
1.5
19.0
22.6
nmol/l
0.88
25
144
12
37
3.58
3.48
1.8
1.8
—
—
—
0
0
23
105
2.59
3.45
5.0
2.2
11.3
14.7
umol/l
1.64
23
98
38
219
2.25
3.42
3.1
3.3
1815.2
1104.9
ng/l
0.55
32
183
38
220
2.24
3.37
6.2
3.7
19.0
11.9
mg/mmol
0.23
21
124
61
434
2.20
3.16
7.0
4.4
7.1
6.6
mmol/l
0.70
56
406
31
169
2.26
3.14
1.8
1.8
449.4
472.3
pmol/l
0.16
23
141
59
420
2.13
2.98
9.5
9.4
3.7
4.0
e9/l
0.62
52
358
52
358
2.04
2.82
16.0
5.8
1.2
1.2
mmol/l
0.82
44
302
45
295
2.03
2.78
2.6
2.1
80.2
76.9
nmol/l
0.33
40
258
40
253
2.03
2.72
5.8
2.8
—
—
—
0
0
19
91
2.37
2.55
3.7
7.9
—
—
—
0
0
44
293
1.96
2.55
4.9
4.1
90.5
48.5
ng/l
0.46
28
205
25
142
2.04
2.22
2.3
1.8
1142.7
1287.0
nmol/l
0.33
19
113
22
120
2.10
2.17
2.5
2.8
0.8
0.8
mmol/l
0.28
22
111
20
105
2.16
2.16
4.2
2.5
1.8
1.2
e6/l
—
5
55
9
34
2.82
1.92
4.4
2.8
66.3
50.5
%
—
9
34
83
731
2.38
1.90
6.1
4.5
6.4
6.0
mmol/l
0.75
74
673
29
183
1.85
1.88
3.8
2.8
401.8
7732.3
umol/l
1.31
24
154
30
196
1.79
1.73
4.7
2.6
0.8
0.3
e6/l
0.52
18
141
5
14
3.71
1.63
5.6
1.4
—
—
—
0
0
24
149
1.83
1.62
1.9
1.7
0.9
1.1
mg/l
0.19
19
119
80
699
2.11
1.62
21.3
13.6
75.5
79.5
ml/min/173m2
0.61
69
559
13
67
2.10
1.47
2.1
1.7
—
—
—
0
0
15
82
1.99
1.46
9.1
5.9
4.9
5.0
kpa
0.22
15
77
80
710
1.97
1.37
9.0
5.6
42.0
40.5
mmol/mol
0.64
71
664
15
85
1.91
1.32
6.4
3.3
—
—
—
0
0
5
18
2.88
1.30
1.6
1.9
—
—
—
0
0
54
440
1.55
1.22
2.9
2.9
—
—
—
0
0
5
20
2.58
1.16
1.2
1.1
—
—
—
0
0
82
746
1.91
1.11
27.8
13.9
24.0
22.7
mg/l
0.16
72
575
65
559
1.55
1.09
6.1
3.9
16.5
12.0
mm/h
1.53
56
507
7
33
2.21
1.08
21.0
5.6
24.6
24.5
mmol/l
—
7
33
9
48
1.97
1.04
14.3
7.0
1.4
1.7
%
—
9
48
66
574
1.53
1.01
4.7
4.0
14.8
14.9
pmol/l
0.04
57
518
43
344
1.47
1.00
4.8
3.7
0.0
0.0
estimate
—
9
68
12
70
1.82
0.98
2.2
1.8
—
—
—
0
0
9
51
1.85
0.98
1.8
1.6
—
—
—
0
0
82
754
1.81
0.95
5.9
5.0
2.7
2.8
mmol/l
0.18
73
689
26
190
1.51
0.93
4.3
3.9
0.0
0.0
estimate
—
9
64
10
57
1.85
0.87
6.2
2.8
37.3
31.8
u/l
—
10
44
85
798
1.86
0.85
17.2
10.1
24.7
25.0
u/l
0.05
85
771
43
353
1.41
0.84
5.0
3.7
0.3
0.0
estimate
—
9
62
77
704
1.57
0.82
5.7
4.7
1.7
1.9
mu/l
0.86
68
641
0
25
0.00
0.80
0.0
1.5
—
—
—
0
0
42
348
1.38
0.76
7.2
4.9
0.0
0.0
estimate
—
9
68
5
24
2.14
0.76
1.0
1.5
—
—
—
0
0
7
40
1.81
0.73
3.1
2.4
0.9
1.2
%
—
7
40
33
268
1.36
0.66
3.6
3.1
2.4
2.4
mmol/l
0.54
28
231
33
269
1.35
0.64
4.5
3.8
—
—
—
0
0
54
486
1.27
0.48
4.8
2.9
77.8
39.6
u/l
1.46
49
461
8
57
1.44
0.43
2.9
5.8
21.6
25.0
mmol/l
—
8
52
75
708
1.32
0.41
5.2
4.0
1.4
1.3
mmol/l
0.87
66
645
10
72
1.44
0.38
2.4
2.1
1.7
1.5
%
—
10
65
11
145
0.73
0.38
1.9
3.3
2.5
2.5
mmol/l
0.88
11
129
78
743
1.33
0.37
5.8
4.4
4.6
4.7
mmol/l
0.58
69
690
6
41
1.50
0.37
1.0
1.4
—
—
—
0
0
8
64
1.27
0.28
8.0
4.0
1.2
1.2
mmol/l
—
8
55
9
72
1.28
0.26
1.9
1.8
—
—
—
0
0
16
133
1.25
0.26
1.3
1.3
13.3
26.7
iu/ml
—
7
50
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
3.1
—
68.4
—
0
8
76
738
1.17
0.17
5.8
4.4
1.4
1.5
mmol/l
0.94
67
678
18
162
1.14
0.13
4.4
4.4
32.1
21.5
%
—
8
76
12
108
1.13
0.07
1.2
1.5
—
—
—
0
0
14
129
1.10
0.06
1.1
1.3
0.9
15.4
u/ml
—
5
45
12
111
1.09
0.04
1.5
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
3.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
13.3
—
0
6
0
5
0.00
0.00
0.0
1.2
—
20.3
—
0
5
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
207.0
—
0
7
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
101.8
—
0
5
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
3.3
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_NAIL_GRYPHOSIS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_NAIL_GRYPHOSIS | 1.729 [1.08, 2.77] | 0.023 |
| Birth year | 0.996 [0.99, 1.0] | 0.325 |
During the follow-up period (1.1.1998 — 31.12.2019), 85 out of 308 females with L12_NAIL_GRYPHOSIS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_NAIL_GRYPHOSIS | 1.993 [1.26, 3.15] | 0.003 |
| Birth year | 0.984 [0.97, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 60 out of 199 males with L12_NAIL_GRYPHOSIS died.
Mortality risk
Mortality risk for people of age
years, who have L12_NAIL_GRYPHOSIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.15% | 0.353% |
| 5 | 0.942% | 2.183% |
| 10 | 2.462% | 5.526% |
| 15 | 4.902% | 10.297% |
| 20 | 8.73% | 16.677% |
Relationships between endpoints
↥Index endpoint: L12_NAIL_GRYPHOSIS – Onychogryphosis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data